Noxxon Pharma Ag

Aptarion Biotech Ag

Cnm Technologies Gmbh

Aptarion Biotech

Christian Maasch

Sven Klussmann

Klaus Buchner

Florian Jarosch

Werner Purschke

Dirk Eulberg

Axel Vater

Nicole Dinse

Kai Hohlig

Dirk Zboralski

Steffen Helmling

Simone Sell

Klaus Schiene

Gregor Bahrenberg

Albert Schnieders

Frank Schwobel

Clemens Gillen

Bernd Eschgfäller

Nikolaus Meyerbröker

Frank Morich

Thorsten Ruppert

Sandra Stark

Elisabeth Moyroud

Mathias Bell

Simone Schulzchen

D Lucas Bethge

Kai HÖHLIG

The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5'-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3′[SEQ. ID. NO: 27], wherein Xu is U or absent.

CXCL8 binding nucleic acids

The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5' AUGnGGUGKUnnRGGGHUGUKGGGnGnCGACGCA 3′ [SEQ ID NO: 61], wherein nis U or dU, nis G or dG, nis A or dA, nis U or dU, nis U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2′-deoxyribonucleotides.

C5a binding nucleic acids

The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5' AUGnGGUGKUnnRGGGHUGUKGGGnGnCGACGCA 3&#x2032; [SEQ ID NO: 61], wherein nis U or dU, nis G or dG, nis A or dA, nis U or dU, nis U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2&#x2032;-deoxyribonucleotides.

The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 87 to 115.

MCP-1 binding nucleic acids

The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.

SDF-1 binding nucleic acids and the use thereof in cancer treatment

The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.

SDF-1 binding nucleic acids and the use thereof

The present invention is related to a method for generating a nucleic acid molecule capable of binding to a target molecule comprising the following steps: a) providing a reference nucleic acid molecule, wherein the reference nucleic acid molecule is capable of binding to the target molecule and wherein the reference nucleic acid molecule comprises a sequence of nucleotides, wherein the sequence of nucleotides comprises n nucleotides; b) preparing a first level derivative of the reference nucleic acid molecule, wherein the first level derivative of the reference nucleic acid molecule differs from the reference nucleic acid molecule at one nucleotide position, wherein the first level derivative is prepared by replacing the ribonucleotide at the one nucleotide position by a 2'-deoxyribonucleotide in case the reference nucleic acid has a ribonucleotide at the nucleotide position and wherein the first level derivative is prepared by replacing the 2&#x2032;-deoxyribonucleotide at the one nucleotide position by a ribonucleotide in case the reference nucleic acid has a 2&#x2032;-deoxyribonucleotide at the nucleotide position and wherein the nucleotide position at which the replacement is made is the modified nucleotide position; and c) repeating step b) for each nucleotide position of the reference nucleic acid molecule, thus preparing a group of first level derivatives of the reference nucleic acid molecule, wherein the group of first level derivatives of the reference nucleic acid molecule consists of n first level derivatives, wherein each of the first level derivatives of the reference nucleic acid molecule differs from the reference nucleic acid molecule by a single nucleotide replacement and wherein each of the first level derivatives of the reference nucleic acid molecule has a single modified nucleotide position which is different from the single modified nucleotide of all of the single modified nucleotide positions of the other first level derivatives of the group of first level derivatives of the reference nucleic acid molecule.

Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

The present invention is related to an L nucleic acid that binds to an SDF-1.

SDF-1 binding nucleic acids

The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115

The present invention is related to a nucleic acid molecule capable of binding to CGRP, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5' HWnnYGGAnAnUMnnYnnnnnKnRnADnnARnUnCnnUnn3&#x2032; [SEQ ID NO: 99], wherein H, W, Y, G, A, U, M, B, K, R, D, C are ribonucleotides, and nis R or dG, nis U or dT, nis K or dG, nis C or dC, nis M or dC, nis B or dU, nis N or dG, nis Y or dT, nis N or dC, nis R or dG, nis V or dA, nis K or dT or dU, nis G or dG, nis A or dA, nis U or dT, nis R or dG, nis Y or dC, nis C or dC, nis B or dC, nis C or dC, nis C or dC, and dG, dT, dC, dA and dU are 2&#x2032;-deoxyribonucleotides.

Nucleic acids specifically binding CGRP

The present invention relates to the use of a L-nucleic acid as intracellularly active agent.

Growing community of inventors

Berlin, Germany

Christian Maasch